Redirecting our immune cells to help fight children's cancer

November 6, 2013
Redirecting our immune cells to help fight children's cancer

Immune cells, known as Natural Killer T cells, could be redirected to help fight the childhood cancer, neuroblastoma, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool (Tuesday).

By genetically modifying human Natural Killer T (NKT) so that they recognise as being dangerous, researchers managed to achieve long-lasting remission - and in some instances cures - of mice that carried highly aggressive human neuroblastoma.

NKT cells are specialised which respond quickly to danger, such as an infection or , and help kick-start an to protect us.

The researchers, from the Texas Children's Cancer Center and Center for Cell & Gene Therapy at the Baylor College of Medicine, have harnessed this ability of NKT cells to act as a warning siren by genetically engineering them to react to a molecule often found on the surface of neuroblastoma tumours known as GD2. It is thought that these modified NKT cells will kill the tumour cells and also reactivate local immune cells that have been tricked into ignoring or even supporting the cancer.

Leonid Metelitsa, professor of paediatrics and immunology at Texas Children's Cancer Center, said: "Tumours often find ways to avoid the immune system or 'switch it off' in order to grow and survive, so any way we can switch the immune system back on and redirect it towards cancer cells would be a significant advance. By modifying these Natural Killer T cells so that they target neuroblastoma tumours and sound the alarm for the rest of the immune system we hope to have developed a new approach to treating this disease."

Neuroblastoma develops from nerve cells left over from a baby's development and there are around 100 children diagnosed with the cancer each year in the UK. Despite the number of children surviving neuroblastoma rising from 17 per cent in 1971 to 64 per cent today, the aggressive form of the disease is still very hard to treat successfully.

Dr Harpal Kumar, chief executive of Cancer Research UK and chair of the NCRI, said: "We are excited to see so much research both here and internationally into badly needed new treatments for neuroblastoma patients. Cutting edge research, such as this study, together with Cancer Research UK's newly opened trials, are making a vitally important step towards better and kinder treatments for children with neuroblastoma."

Explore further: Beta-blockers may boost chemo effect in childhood cancer

Related Stories

Beta-blockers may boost chemo effect in childhood cancer

May 22, 2013
Beta-blockers, normally used for high blood pressure, could enhance the effectiveness of chemotherapies in treating neuroblastoma, a type of children's cancer, according to a new study published in the British Journal of ...

New hope in the fight against childhood cancer

July 11, 2013
Cancer Research UK scientists at the University of Southampton are seeing positive results in a pre-clinical trial that could bring treatments for a particular aggressive form of childhood cancer closer to reality.

Researchers discover how cancer 'invisibility cloak' works

October 28, 2013
Researchers at National Jewish Health have discovered how a lipid secreted by cancer tumors prevents the immune system from mounting an immune response against it. When lysophosphatidic acid (LPA) binds to killer T cells, ...

Immune system discovery could lead to EBV vaccine to prevent mono, some cancers

October 11, 2013
Development of a vaccine against Epstein-Barr virus (EBV) has taken a step forward with the Canadian discovery of how EBV infection evades detection by the immune system.

Dendritic cell vaccine for relapsed neuroblastoma patient induces complete remission

January 29, 2013
One year after his last treatment, a six-year-old boy with recurrent neuroblastoma is in complete remission for his high-risk metastatic cancer. Doctors reported this case study in the January 2013 issue of Pediatrics, the ...

New strategy for defeating neuroblastoma found

June 3, 2013
Researchers at Karolinska Institutet in Sweden have found a promising strategy for defeating neuroblastoma – a malignant form of cancer in children – that focuses on the so-called MYCN protein. A specific chemical molecule ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.